Altre lingue Theratechnologies Inc.

Azioni

TH

CA88338H7040

Mercato chiuso - Toronto S.E. Altri mercati azionari 22:00:00 26/04/2024			Variaz. 5gg	Var. 1 gen.
1,8 ^CAD	0,00%		-0,55%	-15,89%

10/04	Aggiornamento su Theratechnologies; in calo di oltre il 5% sul TSX per la riduzione della perdita netta del primo trimestre, in attesa della decisione della FDA	MT
10/04	Theratechnologies in rialzo di quasi il 6% nel mercato premarket statunitense, dopo aver registrato una perdita netta nel primo trimestre e un'accelerazione della sperimentazione di fase 1 di un farmaco contro il cancro ovarico.	MT

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Theratechnologies Announces Mailing of Management Proxy Circular in Connection with its Annual Meeting of Shareholders	15/04
Theratechnologies to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference	11/04
Update On Theratechnologies; Down More Than 5% On TSX As Q1 Net Loss Narrows, Awaits FDA Decision	10/04
Theratechnologies Up Near 6% In US Premarket As Q1 Net Loss Narrows, Accelerates Phase 1 Trial of Ovarian Cancer Drug	10/04
Theratechnologies: Fiscal Q1 Earnings Snapshot	10/04
Theratechnologies Inc. Reports Earnings Results for the First Quarter Ended February 29, 2024	10/04
Theratechnologies Brief: Citing Acceleration of Phase 1 trial of sudocetaxel zendusortide in advanced ovarian cancer with enrollment of next cohort of patients underway at higher dose level	10/04
Theratechnologies Brief: FY2024 revenue guidance confirmed between US$87-$90 million and an Adjusted EBITDA in the range of $13-15 million	10/04
Theratechnologies Brief: Q1 2024 consolidated revenue of US$16.2 Million; Says Report marks third consecutive quarter of near-flat-to-positive Adjusted EBITDA	10/04
Theratechnologies Reports Financial Results and Provides Business Update for First Quarter 2024	10/04
Theratechnologies Inc. Re-Affirms Earnings Guidance for the Fiscal Year 2024	10/04
North American Morning Briefing : Traders Await -2-	10/04
Theratechnologies Preclinical Data Presentation at AACR 2024 Highlights Versatility and Flexibility of SORT1+ Technology™ Oncology Platform	08/04
Theratechnologies Inc. Preclinical Data Presentation At AACR 2024 Highlights Versatility and Flexibility of SORT1+ Technology? Oncology Platform	08/04
Theratechnologies Appoints Elina Tea to its Board of Directors	05/04
Theratechnologies Inc. Appoints Elina Tea to its Board of Directors and as Member of the Company's Audit Committee	05/04
Theratechnologies to Announce First Quarter 2024 Financial Results and Provide Business Update	03/04
Theratechnologies To Present Preclinical Data at AACR on Multiple PDCs Showcasing Potential of SORT1+Technology Platform	28/03
Theratechnologies Brief: To Present Preclinical Data at AACR on Multiple PDCs Showcasing Potential of SORT1+Technology Platform	28/03
Theratechnologies to Present Preclinical Data at AACR on Multiple PDCs Showcasing Potential of SORT1+Technology™ Platform	28/03

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Theratechnologies Inc.

Azioni

TH

CA88338H7040

Altre lingue

Filtri